Dynavax Technologies Corporation (NASDAQ:DVAX)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen and Company in a research note issued to investors on Friday. They presently have a $30.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s price objective points to a potential upside of 38.89% from the stock’s current price.

The analysts wrote, “Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in.””

Several other research firms have also recently weighed in on DVAX. William Blair restated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Royal Bank Of Canada restated an “outperform” rating and issued a $28.00 price objective (up previously from $26.00) on shares of Dynavax Technologies Corporation in a research report on Monday, September 25th. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $27.00 in a research report on Monday, July 31st. Finally, BidaskClub cut shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $25.00.

Dynavax Technologies Corporation (NASDAQ:DVAX) traded up $0.60 on Friday, reaching $21.60. 1,292,820 shares of the company’s stock traded hands, compared to its average volume of 1,408,759.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.15. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.28 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company’s quarterly revenue was down 68.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.90) EPS. equities research analysts forecast that Dynavax Technologies Corporation will post -1.74 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-earns-buy-rating-from-cowen-and-company/1676319.html.

Several large investors have recently modified their holdings of DVAX. Cubist Systematic Strategies LLC grew its position in shares of Dynavax Technologies Corporation by 54.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC grew its position in shares of Dynavax Technologies Corporation by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares during the period. Bank of America Corp DE grew its position in shares of Dynavax Technologies Corporation by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the period. Legal & General Group Plc grew its position in shares of Dynavax Technologies Corporation by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the period. Finally, Wall Street Access Asset Management LLC acquired a new stake in shares of Dynavax Technologies Corporation during the 2nd quarter worth approximately $124,000. Institutional investors own 59.90% of the company’s stock.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.